Lung Fluid Balance and Mesenchymal Stem Cells

肺液平衡和间充质干细胞

• 批准号: 8286345
• 负责人: MICHAEL A. MATTHAY
• 金额: $ 38.24万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-12-01 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8286345
• 关键词: Acute; Acute Lung Injury; Acute respiratory failure; Adherent Culture; Allogenic; Alveolar; Anti-Inflammatory Agents; Anti-inflammatory; Attenuated; Biology; Blocking Antibodies; Brain Death; Cell Therapy; Cells; Clinical; Data; Dose; Edema; Endotoxins; Epithelial; Epithelial Cells; Escherichia coli; Fluid Balance; Growth Factor; Harvest; Hepatocyte Growth Factor; Human; Hydrochloric Acid; Inflammatory; Inflammatory Response; Interferons; Interleukin-1; Interleukin-10; Intravenous; Knockout Mice; Knowledge; Life; Liquid substance; Lung; Mediating; Mesenchymal Stem Cells; Modeling; Morbidity - disease rate; Mus; Patients; Play; Pneumonia; Preparation; Pulmonary Edema; Research Proposals; Resolution; Role; Secondary to; Severities; Stimulus; TNF gene; Testing; Therapeutic; Therapeutic Effect; Therapeutic Studies; Time; Translating; Type II Epithelial Receptor Cell; Undifferentiated; United States; Work; alveolar type II cell; anakinra; base; clinically relevant; cytokine; design; improved; in vitro Model; injured; innovation; insight; keratinocyte; lung injury; mortality; mouse model; novel strategies; protective effect; research study; response; stem cell therapy

DESCRIPTION (provided by applicant): Acute respiratory failure from acute lung injury is a major clinical problem with substantial mortality and morbidity. The overall objective of this proposal is to test the value of cell-based therapy with mesenchymal stem cells (MSC) for the treatment of experimental acute lung injury and restoring normal lung fluid balance in acute lung injury. Aim 1 is designed to determine the therapeutic effects of intrapulmonary and intravenous delivery of MSC on pulmonary edema and survival in clinically relevant mouse models of acute lung injury. Aim 2 will evaluate the mechanisms responsible for the beneficial effects of MSC treatment in the clinically relevant models of pulmonary edema from acute lung injury in mice studied in Aim 1, with a specific focus on the role of interleukin-1 receptor antagonist (IL-1ra) and interleukin-10. Aim 3 is designed to test the therapeutic and mechanistic effects of allogeneic human MSC on restoring alveolar epithelial fluid transport in an in vitro model of cultured human alveolar epithelial type II cells and in an ex vivo perfused human lung preparation. The proposed studies in Aims 1 and 2 will advance our understanding of the mechanisms by which MSCs reduce lung injury and pulmonary edema as well as advance our knowledge of the biology of MSCs in the setting of acute lung injury in mice. Aim 3 will translate these findings to the human lung by using cultured monolayers of polarized human alveolar epithelial type II cells and an ex vivo perfused human lung preparation. The results of these experiments will help make it possible to determine whether testing MSCs in patients with acute lung injury is appropriate. The proposed work will also uncover mechanisms by which MSC reduces pulmonary edema from acute lung injury, and these insights will advance the fields of lung fluid balance, pulmonary edema, and acute lung injury. PROJECT NARRATIVE. This research proposal has direct relevance to the clinical problem of acute respiratory failure from pulmonary edema secondary to acute lung injury, a cause of morbidity and mortality in the United States. The proposal will test novel strategies to use cell based therapy for the treatment of experimental acute lung injury including mouse models of lung injury as well as innovative models that use human lung epithelial cells and intact human lungs harvested from brain dead subjects.

描述（由申请人提供）：急性肺损伤引起的急性呼吸衰竭是一个重要的临床问题，死亡率和发病率都很高。本提案的总体目标是测试间充质干细胞（MSC）细胞为基础治疗实验性急性肺损伤和恢复急性肺损伤正常肺液平衡的价值。Aim 1旨在确定肺内和静脉给药MSC对急性肺损伤临床相关小鼠模型肺水肿和存活的治疗作用。Aim 2将评估MSC治疗在Aim 1研究的小鼠急性肺损伤肺水肿临床相关模型中有益作用的机制，特别关注白细胞介素-1受体拮抗剂（IL-1ra）和白细胞介素-10的作用。目的3是在体外培养的人肺泡上皮II型细胞模型和体外灌注的人肺制剂中，测试同种异体人间充质干细胞对恢复肺泡上皮液体运输的治疗和机制作用。在目标1和目标2中提出的研究将促进我们对MSCs减少肺损伤和肺水肿的机制的理解，并推进我们对MSCs在小鼠急性肺损伤环境中的生物学知识。目的3将利用培养的极化人肺泡上皮II型细胞单层和离体灌注人肺制备物，将这些发现转化为人肺。这些实验的结果将有助于确定在急性肺损伤患者中检测MSCs是否合适。这项工作还将揭示MSC减少急性肺损伤引起的肺水肿的机制，这些见解将推动肺液平衡、肺水肿和急性肺损伤领域的发展。项目的叙述。这项研究计划与急性肺损伤继发肺水肿急性呼吸衰竭的临床问题直接相关，这是美国发病率和死亡率的一个原因。该提案将测试使用细胞疗法治疗实验性急性肺损伤的新策略，包括肺损伤小鼠模型，以及使用人类肺上皮细胞和从脑死亡受试者中采集的完整人类肺的创新模型。

项目成果

Mitochondrial Transfer via Tunneling Nanotubes is an Important Mechanism by Which Mesenchymal Stem Cells Enhance Macrophage Phagocytosis in the In Vitro and In Vivo Models of ARDS.

• DOI: 10.1002/stem.2372
• 发表时间: 2016-08
• 期刊: Stem cells (Dayton, Ohio)
• 作者: Jackson MV;Morrison TJ;Doherty DF;McAuley DF;Matthay MA;Kissenpfennig A;O'Kane CM;Krasnodembskaya AD
• 通讯作者: Krasnodembskaya AD

Novel role for CFTR in fluid absorption from the distal airspaces of the lung.

CFTR在肺部远端空域吸收流体吸收中的新作用。

• DOI: 10.1085/jgp.119.2.199
• 发表时间: 2002-02
• 期刊: JOURNAL OF GENERAL PHYSIOLOGY
• 影响因子: 3.8
• 作者: Fang, X;Fukuda, N;Barbry, P;Sartori, C;Verkman, A S;Matthay, M A
• 通讯作者: Matthay, M A

Donor smoking is associated with pulmonary edema, inflammation and epithelial dysfunction in ex vivo human donor lungs.

• DOI: 10.1111/ajt.12853
• 发表时间: 2014-10
• 期刊: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
• 作者: Ware LB;Lee JW;Wickersham N;Nguyen J;Matthay MA;Calfee CS;California Transplant Donor Network
• 通讯作者: California Transplant Donor Network

Role of collagenase in mediating in vitro alveolar epithelial wound repair.

胶原酶在介导体外肺泡上皮伤口修复中的作用。

• DOI: 10.1242/jcs.112.2.243
• 发表时间: 1999
• 期刊: Journal of cell science
• 影响因子: 4
• 作者: Planus,E;Galiacy,S;Matthay,M;Laurent,V;Gavrilovic,J;Murphy,G;Clérici,C;Isabey,D;Lafuma,C;d'Ortho,MP
• 通讯作者: d'Ortho,MP

Conference summary: acute lung injury.

会议摘要：急性肺损伤。

• DOI: 10.1378/chest.116.suppl_1.119s
• 发表时间: 1999
• 期刊: Chest
• 影响因子: 9.6
• 作者: Matthay,MA